Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FRA:R9Z's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 13.8
vs FRA:R9Z: -2.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ImmuneOnco Biopharmaceuticals (Shanghai)'s PE Ratio (TTM) for today is calculated as:
ImmuneOnco Biopharmaceuticals (Shanghai)'s share price for today is €0.388.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ImmuneOnco Biopharmaceuticals (Shanghai)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.064.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:R9Z vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuneOnco Biopharmaceuticals (Shanghai) EV-to-EBITDA vs Biotechnology Industry
ImmuneOnco Biopharmaceuticals (Shanghai)'s current Enterprise Value is €74.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ImmuneOnco Biopharmaceuticals (Shanghai)'s EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-25.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a EV-to-EBITDA of -2.87 as of Sep. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai). According to the industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #999999 out of 402 companies in the Biotechnology industry.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-EBITDA too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current EV-to-EBITDA is -2.87. Based on the distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #999999 out of 402 companies for EV-to-EBITDA. This places ImmuneOnco Biopharmaceuticals (Shanghai) in the lower half of its industry. The industry median EV-to-EBITDA is 13.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai). For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmuneOnco Biopharmaceuticals (Shanghai)'s current EV-to-EBITDA is -2.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a current EV-to-EBITDA of -2.87. The current EV-to-EBITDA is -2.87. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z), the current EV-to-EBITDA is -2.87 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
7GF Score
Get the complete analysis for FRA:R9Z
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:R9Z has been successfully added to your 
